Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe







